Journal of Diabetes & Metabolism

ISSN - 2155-6156

+441518081309

Research Article - (2012) Volume 3, Issue 10

Protective Effect of Camel Milk and Ginkgo biloba Extract Against Alloxan-Induced Diabetes in Rats

Nahla S Hassan* and Manal A Emam
Biochemistry Department, Ain Shams University, Cairo, Egypt
*Corresponding Author: Nahla S Hassan, Biochemistry Department, Faculty of Science, Ain Shams University, Cairo 11566, Egypt, Tel: 01002278483 Email:

Abstract

Diabetes Mellitus is one of the most important health problems worldwide, indicating high prevalence and mortality. In recent years, Ginkgo biloba extract has become a subject of interest because of its beneficial effects on human health, also camel milk has a good nutritive value, in addition to its antigenotoxic and anticytotoxic effects. Therefore the purpose of the present study was to investigate the protective and curative effects of camel milk and Ginkgo biloba extract against alloxan-induced diabetes in rats.

Rats were either pre-treated with camel milk, Ginkgo biloba extract or both, for 10 days before alloxan administration, or treated with both camel milk and Ginkgo biloba extract after induction of diabetes using alloxan.

Pre-treatment of rats with either camel milk or Ginkgo biloba extract significantly prevented the alloxan-induced elevation of blood glucose levels. The combination of camel milk and Ginkgo biloba extract before and after induction of diabetes prevented and improved blood glucose levels respectively.

Keywords: Diabetes mellitus; Ginkgo biloba; Camel milk; Alloxan; Oxidative stress; Total antioxidant activity

Introduction

Diabetes mellitus is a common disorder associated with marked increase in morbidity and mortality rate. Diabetes mellitus can be defined as a group of metabolic diseases characterized by chronic hyperglycemia resulting from defects in insulin secretion, insulin action or both, resulting in impaired function in carbohydrate, lipid and protein metabolism [1,2]. There is a reservoir of basic information that suggests the involvement of oxidative stress in the pathogenesis of diabetes mellitus. It is now recognized that sustained hyperglycemia in diabetic patient, causes protein glycation and generates free radicals through auto-oxidation and polyol pathways [3,4].

High levels of free radicals with concurrent decline of antioxidant defense mechanism may lead to damage of cellular organelles and enzymes [5]. This can culminate in increased lipid peroxidation and development of insulin resistance, which may consequently promote the development of complications of diabetes mellitus [6].

In humans, diabetes mellitus is one of the most prevalent conditions with spontaneous manifestation. In animals, it can be induced by partial pancreatectomy or by the administration of diabetogenic drugs such as alloxan, streptozotocin, ditizona and anti-insulin serum [7]. These agents selectively destroy the Langerhans islet β-cells. One of the best known drug-induced diabetes models is the alloxan diabetes. Alloxan (a derivative of uric acid) as well as of other substances of different chemical groups, cases β-cells to degranulate and consequently degenerate. Alloxan induces irreversible diabetes mellitus 24 hours following its administration and the condition proves to be chronic by laboratory tests after seven days [8,9].

Insulin therapy and oral hypoglycaemic agents offer effective glycaemic control, but insulin therapy has shortcomings such as ineffectiveness following oral administration, short shelf life, the need for constant refrigeration, and fatal hypoglycaemia, in the event of excess dosage [10]. As a result, there is a need to search for compounds with effective antidiabetic activity when taken orally. The oral hypoglycemic agents that are capable of reducing blood sugar level belong to two chemical classes; sulfonylureas and biguanides [11]. However, the use of oral antidiabetics is limited due to their adverse side effects including hematological, cutaneous and gastrointestinal reactions, hypoglycaemic coma and disturbances of liver and kidney functions. In addition, they are not suitable for use during pregnancy [12].

Plants are well known in traditional herbal medicine for their hypoglycaemic activities, and available literature indicate that there are more than 800 plant species showing hypoglycaemic activity [13]. The World Health Organization has recommended the evaluation of the effectiveness of plants in conditions, where safe orthodox drugs are scarce [14]. Studies have shown that phytochemicals isolated from plant sources have been used for the prevention and treatment of cancer, heart disease, diabetes mellitus, and high blood pressure [15].

Over the past few years, the use of medicinal plants has been rapidly increasing. The therapeutic benefits of these plants are often attributed to their antioxidant properties [16].

The tree Ginkgo biloba has long been believed to have medicinal properties, and its extracts are among the most widely-sold herbal supplements in the world. Ginkgo biloba extract (GbE), prepared from Ginkgo biloba leaves, is defined as a complex mixture containing 24% Ginkgo flavoneglycoside (quercetin, kaempferol, and isorhamne) and 6% terpene lactones (ginkgolides and bilobalide). It has been used as a therapeutic agent in some cardiovascular and neurological disorders [17,18].

The beneficial effects of GbE might be channeled through a combination of one or several mechanisms of action. The combined therapeutic effects are probably greater than that of individual mechanisms and are perhaps the result of the synergistic effects of multiple constituents of the total extract [19]. The chemical structure of GbE 761, both flavonoid and ginkgolide constituents, is responsible for its remarkable antioxidant/reactive oxygen nitrogen species (RONS) scavenging activity. The flavonoids preferentially react with hydroxyl radicals [20] and chelate pro-oxidant transition heavy metal ions [21]. Significant antioxidant activity is consequently one of the most analyzed protective effects of GbE on the central nervous system and the circulatory system. GbE has a number of benefits, including ameliorating hemodynamics, suppressing the platelet-activating factor, scavenging reactive oxygen species (ROS), and relaxing vascular smooth muscles [22]. Nowadays, extract of Ginkgo leaves in the form of film-coated tablets, oral liquids or injectable solutions are being used [23]. All of these criteria offered a pharmacological foundation for testing GbE for diabetic therapy.

Camel milk (CM) is an excellent source of well-balanced nutrients and also exhibits a range of biological activities that influence digestion, metabolic responses to absorbed nutrients, growth and development of specific organs and resistance to diseases. These biological activities are mainly due to the presence of peptides and proteins in milk [24,25]. CM is different from other ruminant milk; having low cholesterol, low sugar, high minerals (sodium, potassium, iron, copper, zinc and magnesium) and high vitamin C, B2, A and E. It has no allergic properties and it can be consumed by lactase deficient persons and those with weak immune systems. The milk is considered to have medical properties. A series of metabolic and autoimmune diseases are successfully being treated with CM [26].

Casein is the principal protein component in most of the mammalian milk. Besides casein CM also contains lactoferrin protein. It also contains fat with a relatively large amount of polyunsaturated fatty acids and linoleic acids, which are essential for human nutrition [27]. The anti-cytotoxic and antigenotoxic effects of most of the CM constituents against the genotoxic effects of chemicals are being investigated (e.g. vitamin C [28-30], selenium [31-33], zinc [34], casein [35,36] and lactoferrin) [37].

In India, CM is used therapeutically against dropsy, jaundice, problems of spleen, tuberculosis, asthma, anemia, piles and diabetes [38]. Beneficial role of raw CM in chronic pulmonary tuberculosis patients has been observed [39]. In repeated trials, it was observed that there was 30-35% reduction in daily doses of insulin in patient of type 1 diabetes receiving raw CM [40].

In this study, the effect of oral dietary supplementation of CM and/ or GbE in the prevention and/or treatment of alloxan induced diabetes in rat model was investigated. We also investigated the potential role of antioxidant activity of both materials in protecting from diabetes.

Materials and Methods

Animals

Male Wistar rats, weighing 180-220 g, were obtained from the animal house Medical Research Center. Animals were housed in polyplastic cages with steel wire tops in an air conditioned room maintained in a controlled atmosphere of 12 h light/12 h dark cycles with free access to a standard commercial diet and water.

Test compounds

Camel milk: Camel milk samples were collected from a Camel farm in Ras Seder, Egypt. All lactating camels consumed the same type of food. The milk was collected in the morning in sterile screw bottles and kept on ice during transportation to the laboratory where milk bottles were stored at 4°C. It was administered in a dose of 33 ml/kg body weight for each rat daily by oral cannula.

Ginkgo biloba extract (GbE761): Ginkgo biloba extract (lot No 04002) was provided by Changsha Sunfull Bio-tech company (China) and was dissolved in 30% poly ethylene glycol 400 (PEG , pH 7.4). It was used in a dose of 100 mg/kg.b.w. daily by intraperitoneal injection.

Induction of diabetes

Diabetes was induced in fasting rats 12 h by a single intraperitoneal injection of freshly prepared alloxan (120 mg/kg body weight, dissolved in 0.9% saline, Sigma Chemicals, USA). After 48 h of alloxan treatment, rats with marked hyperglycemia (fasting blood glucose >200 mg/ dl) were selected for the experiment and considered as diabetic. The experimental animals were divided into 9 groups; each group contained 8 animals. Body weight and fasting blood glucose levels were estimated on 2nd, 4th, 7th and 10th day of the treatment. On the 10th day, blood samples were collected from overnight fasted rats by cardiac puncture under mild ether anesthesia for biochemical estimations.

Experimental design

The various groups used in the experiment:

Group N: Normal control rats did not receive any treatment.

Group CM: Normal rats received CM daily for ten days.

Group GbE: Normal rats received GbE daily for ten days.

Group CM + GbE: Normal rats receive both CM and GbE daily for ten days.

Group D: Diabetic control rats, which received alloxan monohydrate only.

Group P CM: Rats received CM daily for ten days before alloxan treatment.

Group P GbE: Rats received GbE daily for ten days before alloxan treatment.

Group P CM+GbE: Rats received both CM and GbE daily for ten days before alloxan treatment.

Group T: Diabetic rats (alloxan-induced) received both CM and GbE daily for ten days following alloxan injection.

Biochemical investigations

Determination of blood glucose concentration: Fasting blood glucose concentration was determined by commercially available glucose kit (Egy-Chem) based on Trinder’s [41] glucose oxidase method. The glucose levels were expressed as mg/dl.

Determination of insulin and C-peptide concentration: Insulin concentration was determined in serum by radioimmunoassay method using a commercially available DSL-1600 insulin kit (Diagnostic Systems Laboratories, Inc., USA). Insulin values were expressed as μU/ ml.

Biochemical parameters of oxidative stress:

Determination of the lipid peroxidation (LPO) in serum: Malondialdehyde (MDA) was measured by the method of Ohkawa et al. [42] and read fluorimetrically at excitation wavelength of 532 nm and emission at 553 nm.

Total antioxidant activity estimation: Total antioxidant activity (TAA) was assessed by the method of Koracevic et al. [43] using bio-dignostic kit (Egy-Chem).

Determination of liver function tests: Liver function tests, including liver enzymes (Alanine transaminase (ALT), Aspartate transaminase (AST) [44]) and gamma glutamyl transferase (GGT) [45], lipid profile (Total cholesterol (TC) [46], High density lipoprotein cholesterol (HDL) [47] and Triglycerides (TG) [48]) and total proteins [49] were determined using bio-diagnostic kits (Egy-Chem).

Kidney function tests: Kidney function tests, including determination of urea [50] and creatinine [51] in serum were done using bio-diagnostic kits (Egy-Chem).

Pancreatic histopathology

Autopsy samples were taken from Pancreas of rats in different groups and fixed in 10% formalin for twenty four hours. Washing was done in tap water then serial dilutions of alcohol (methyl, ethyl and absolute ethyl) were used for dehydration. Specimens were cleared in xylene and embedded in paraffin at 56° in hot air oven for twenty four hours. Paraffin bee wax tissue blocks were prepared for sectioning at 4 microns by sliding microtome. The obtained tissue sections were collected on glass slides, deparaffinized and stained by hematoxylin and eosin stains [52] for histopathological examination through the electric light microscope.

Data analysis

Data were statistically analyzed using the Statistical Package for Social Sciences (SPSS) version 17. Hypothesis testing was done by oneway analysis of variance (ANOVA).

Results

In order to evaluate the protective and/or therapeutic potential of individual or combined treatment with CM and GbE, rats were either pretreated for 10 days with CM, GbE, or both, prior to induction of diabetes using a single injection of alloxan, or treated with both compounds for 10 days after the alloxan treatment.

A significant increase in blood glucose levels, at day 2 post alloxan treatment, was observed in the alloxanized diabetic group by 180 %, (p<0.001) (Figure 1), compared to the non-diabetic one. Administration of both CM and GbE along with alloxan caused a significant reduction in the blood glucose levels by 46.7%, (p<0.001) as compared to the diabetic control rats.

diabetes-metabolism-Fasting-blood

Figure 1: Fasting blood glucose levels in normal, diabetic and treated groups. Data were represented as mean+S.E FBG: Fasting Blood Glucose.

Treatment of control rats with GbE and CM showed normal levels of insulin and C-peptide as compared with untreated control animal. Notably pre-treatment with GbE, CM or both before alloxan revealed no significant change in results compared to normal control rat. Alloxan- induced diabetic rats showed severe hypoinsulinemia and low level of C- peptide (p<0.001; Table 1) as compared with normal control rats. The administration of GbE and CM to alloxanized diabetic rats partially restored serum insulin level (p<0.05).

Moreover, less weight gain was observed in the diabetic rats as compared to the control. Administering GbE and CM improved the weight gain in the alloxan-induced diabetic rats.

Groups Insulin μmU/ml C-Peptide ng/ml
N 25.15± 1.41* 2.24±0.05*
CM 29.9± 0.47* 2.47±0.02*
GbE 29.3± 0.74* 2.44±0.04*
CM+GbE 34.2± 0.47* 2.74±0.02*
D 4.47± 0.11 0.18±0.01
P CM 29.5± 0.28* 2.45±0.02*
P GbE 29.9± 0.49* 2.48±0.03*
P CM+ P GbE 35.2± 0.48* 2.81±0.03*
T 18.5± 0.70* 1.63±0.04*
Results are represented as mean+S.E *Statistical significance at p<0.05

Table 1: Effect of pre-and post-treatment with CM and GbE on the levels of insulin and C-peptide in alloxan-induced diabetic rats.

Effect of the different treatments on serum ALT, AST and GGT activities and total proteins is presented in figure 2. Treatment of control rats with GbE and/or CM did not significantly alter the ALT, AST and GGT activities and total protein levels as compared to normal control rats. Meanwhile alloxan-induced diabetes induced a highly significant increase in ALT, AST and GGT activities and decrease in total proteins levels (p<0.001) as compared to normal control ones. Importantly, administration of GbE and CM to alloxan-induced diabetic rats significantly improved the enzymes and total protein levels (p<0.001) as compared to diabetic group.

diabetes-metabolism-post-treatment

Figure 2: Effect of pre-and post-treatment with CM and GbE on the (A) activity of Serum transaminases (B) GGT (C) Total proteins (D) Lipid profile (TC, TG and HDL) in alloxan-induced diabetic rats. Results are represented as mean+S.E.

Serum lipid parameters (TC, TG and HDL cholesterol) were not affected by the administration of GbE and/or CM to normal rats as compared to the control group (group N), whereas alloxan-induced diabetic rats showed marked increase in TG and TC (p<0.001). Meanwhile, GbE and CM treatment of diabetic rats, in group T, caused a significant decrease in the previous parameters compared to the diabetic values (p<0.001). The values of HDL were found to be significantly increased in control groups (groups CM, GbE& CM+GbE) when compared with normal control (p<0.05), while alloxan diabetic rats recorded a highly significant decrease when compared to normal control group (p<0.001). Treatment with CM and GbE tested materials (group T) caused a significant increase in HDL cholesterol levels when compared to diabetic control group (p<0.001) as indicated in figure 2.

Figure 3 shows a marked increase in serum urea and creatinine levels in diabetic control rats compared to normal control ones. Pre-and post-treatment with CM and/or GbE induced a significant improvement of the urea and createnine levels compared to diabetic control (group D).

diabetes-metabolism-creatinine-conc

Figure 3: Effect of pre –and post treatment with CM and GbE on serum (A) urea and (B) creatinine conc. Results are represented as mean+S.E.

Our results indicate that TAA levels were markedly decreased in diabetic group. It was observed that the treatment with GbE and CM caused an increase in TAA compared to diabetic control (Figure 4A). In the control groups (CM, GbE and GbE+CM) there is a significant increase in TAA level compared to normal control group (N).

Figure 4B, showed a significant elevation of plasma MDA content in diabetic rats compared to normal control. In the treated group (T) there is significant decrease in MDA compared to diabetic rats (group D),while in groups CM and CM+GbE there is a non significant decrease in MDA level compared to normal control group (group N).

diabetes-metabolism-antioxidant-activity

Figure 4: (A) Serum total antioxidant activity (TAA) (B) Malondialdehyde (MDA) in all groups.

Histopathological findings

Group N: There was no histopathological finding and the normal histological structure of the islands of Langerhans cells as endocrine structure, the acini as exocrine one and the interlobular blood vessels were recorded in (Figure 5A).

diabetes-metabolism-eosin-stained

Figure 5: Hematoxylin and eosin- stained sections of rat pancreas: (A) represents normal control group showing numerous beta cells with abundant basophilic cytoplasm (B,C,D) represents normal treated groups with CM, GbE ,and CM+GbE ,respectively showing normal histological structure of islands of langerhans cells (E): represents alloxan treated rats showing atrophy of the beta cells associated with congestion in the interlobular blood vessels (F,G,H) represents pancreatic section of pretreated groups with CM, GbE and CM GbE showing normal histological structure of islands of langerhans cells (I) represents pancreatic section of diabetic treated rats showing regeneration of beta cells with mild atrophy was observed in the islands of Langerhans (HE × 400).

Groups CM, GbE and CM+GbE respectively: There was no histopathological alternation in the islands of Langerhans (Figure 5B-5D).

Group D: Atrophy was noticed in the islands of Langerhans, associated with congestion in the interlobular blood vessels (Figure 5E).

Groups P CM, P GbE and P CM+GbE respectively: There was no histopathological alternation detected in the islands of Langerhans (Figure 5F-5H).

Group T: There was a mild atrophy in the islands of Langerhans as recorded in figure 5I.

Discussion

Diabetes mellitus (DM) is possibly the world’s fastest growing metabolic disorder. It is one of the most important health problems worldwide, indicating high prevalence and mortality. Management of diabetes without any side effects is still a challenge to medical communities, therefore herbal and natural products with anti-diabetic activity and fewer side effects are strongly needed [53].

In this study, the pancreatic β cells were destroyed using alloxan, a toxic glucose analogue that accumulate in pancreatic beta cells via GLUT 2 glucose transporter. In the presence of thiols, especially glutathione (GSH), alloxan generates reactive oxygen species (ROS) in cyclic redox reactions. The reduction product of alloxan is dialuric acid. Auto-oxidation of dialuric acid generates ROS, which are responsible for the death of the β cells. Alloxan also inhibits glucose-induced insulin secretion through its ability to inhibit the β cell glucose sensor, glucokinase. Inappropriate activation of NFκB by ROS might start a cascade of events that result in an inflammatory and autoimmune response in pancreas, so the inhibition of NFκB activation by antioxidants could improve the severity of type 1diabetes [54,55]. In the present study, it can be concluded that pre-treatment with camel milk (CM) and/or Ginkgo biloba (GbE) may inhibit alloxan–induced NFκB activation.

Post-treatment with CM and GbE didn’t decrease the blood glucose level back to normal levels where it was still significantly higher than normal. However the pre-administration of CM and GbE before alloxan treatment protected the β-cells from damage and the level of blood glucose was non-significantly different from that of normal rats. It was found that one of the CM proteins presents many characteristics similar to insulin [56] and does not form coagulum in acidic environment. This lack of coagulum formation allows CM to rapidly pass through the stomach, without being destroyed, together with the specific insulin like protein/insulin and remains available for absorption in the intestine. Radioimmunoassay of insulin in CM has revealed high concentration (52 units/liter) [57]. This suggests a very low prevalence of diabetes among subjects that are consuming CM [40].

In addition, administration of GbE and CM caused marked amelioration of serum glucose concentration of alloxan diabetic rats, besides elevating insulin and C-peptide concentrations which were reduced by alloxan administration. Our data are in good agreement with other investigators [58-60] who stated that the positive effects of specific plant extracts on insulin activity suggest a possible role of these plants in improving glucose and insulin metabolism.

The anti-hyperglycemic effects of CM and GbE are possibly linked to their antioxidant properties, which could counteract the toxic and pro-oxidant effects of alloxan. Flavonoids, sterols/triterpenoids, alkaloids and phenolics are known to be bioactive anti-diabetic principles [61-64]. Flavonoids are known to regenerate the damaged β cells in the alloxan diabetic rats [65]. Phenolics were also found to be effective anti-hyperglycemic agents [66,67].

It is evident that increased hepatic glucose output in diabetes mellitus may be derived either from glycogenolysis or from gluconeogensis or both [68,69]. This was confirmed by our results which showed a marked increase of the detected gluconeogenic serum enzymes; Alanine transaminase (ALT), Aspartate transaminase (AST) and gamma glutamyl transferase (GGT); compared to those of the nondiabetic ones. Our study demonstrated that, the administration of GbE and CM resulted in the attenuation of liver injury induced by alloxan treatment as indicated by the activities of ALT, AST and GGT. These results are in accordance with those of Rawi et al. [69], who found that the decrease of transaminases activities with treatment may be attributed to improved liver function with the return of gluconeogensis towards its normal rate.

In the present study, alloxan diabetic rats exhibited marked hypertriglyceridemia, hypercholesterolemia with concomitant decrease in HDL cholesterol. Our results are in accordance with the findings of Mathe [70], Ulicna et al. [71] and Wasan et al. [72] who recorded marked increases of serum triglycerides and cholesterol levels and abnormalities in lipoprotein levels in alloxan and streptozotocin diabetic animals. These abnormalities certainly play a role in the increased risk for cardiovascular disease [73].

The abnormally high concentration of plasma lipids in diabetes is mainly due to the increase in the mobilization of free fatty acids from the peripheral depots, since insulin inhibits the hormone sensitive lipase [73]. The marked hyperlipidemia that characterizes the diabetic state may therefore be regarded as a consequence of the unlimited actions of lipolytic hormones on the fat depot [74]. Treatment of alloxan diabetic rats with GbE and CM produced marked decrease of serum triglycerides and total cholesterol concentrations. These observations indicate that the hypocholesterolemic action of the tested materials might be attributed to their ability to suppress cholesterol biosynthesis. Furthermore, correlation between insulin levels, triglycerides and cholesterol fractions underline the important role of this hormone in the control of blood lipid levels [75].

Oxidative stress may constitute the key and common events in the pathogenesis of different diabetic complications. [76]. Hypoinsulinemia in diabetes increases the activity of the enzyme fatty acyl coenzyme A oxidase which initiates β oxidation of fatty acids, resulting in lipid peroxidation [77,78]. The present study showed a significant elevation of plasma malondialdehyde (an indicator of lipid peroxidation) contents in diabetic rats. The GbE and CM significantly reduced the lipid peroxidation product levels in diabetic rats, confirming that GbE and CM are potent antioxidants.

Any compound – natural or synthetic – with antioxidant activity might totally or partly alleviate the oxidative damage [76]. Total antioxidant activity (TAA) reflects the ability to defend against free radical damage more precisely than measurement of individual plasma antioxidants, since TAA is a result of interactions among its various components. Our results indicate that TAA levels were markedly decreased in the diabetic group. It was observed that treatment with GbE and CM caused an increase in TAA.

Alloxan was found to cause a significant reduction in the body weight of rats when compared with the control. Animals receiving GbE and CM, both pre- and post-treatment, with alloxan increased their body weight compared with the diabetic rats. Suresh and Das [79] reported that animals which developed alloxan-induced DM showed a significant decrease in body weight as a result of uncontrolled DM. The ability of GbE and CM to prevent and/or correct body weight loss seems to be due to its hypoglycaemic and hypolipidemic effects.

Plasma urea and creatinine can be used as a rough index of the glomerular filtration rate [80]. High levels of urea and creatinine indicates several disturbances in kidney [81]. In this study, the treatment with GbE and CM (pre and post-treatment) significantly increased serum total proteins and decreased serum urea and creatinine levels, compared to alloxan diabetic rats by enhancing the renal function that is generally impaired in diabetic rats.

The prevention of chemically-induced DM in experimental animals by polyunsaturated fatty acids was studied by Mohan and Das [82]. They observed that oral supplementation with oils rich in ?ˆ-3 (EPA, DHA) and ?ˆ-6 (linolenic, arachidonic) fatty acids could protect the animals against alloxan induced DM. These oils not only significantly attenuated the chemically-induced DM, but also restored the antioxidant status to a normal range by suppressing production of cytokines [83]. The protective effect of camel milk may be because it also contains fat with a relatively large amount of polyunsaturated fatty acids and linoleic acids.

Finally, it is concluded that the consumption of GbE and CM caused a significant reduction in glucose level of alloxan diabetic rats. In addition, those agents were capable of improving hyperlipidaemia and the impaired kidney functions. Moreover, the pretreatment of rats with GbE and/or CM for 10 days before induced diabetes was effective in controlling the hyperglycemia, hyperlipidaemia and the oxidative damage.

References

  1. Gillett MJ (2009) International expert committee report on the role of the AIC assay in the diagnosis of diabetes. Diabetes Care 2009. Clin Biochem Rev 30:197-200.
  2. Zhang J, Huang Y, Hou T, Wang Y (2006) Hypoglycaemic effect of Artemisia sphaerocephala Krasch seed polysaccharide in alloxan-induced diabetic rats. Swiss Med Wkly 136:529-532.
  3. Ramakrishna V, Jailkhani R (2008) Oxidative stress in non-insulin-dependent diabetes mellitus (NIDDM) patients. Acta Diabetol 45:41-46.
  4. Sharma SB, Nasir A, Prabhu KM, Murthy PS, Dev G (2003) Hypoglycaemic and hypolipidemic effect of ethanolic extract of seeds of Eugenia jambolana in alloxan-induced diabetic rabbits. J Ethnopharmacol 85:201-206.
  5. Ottaviano FG, Handy DE, Loscalzo J (2008) Redox regulation in the extracellular environment. Circ J 72:1-16.
  6. Demozay D, Mas JC, Rocchi S, Van Obberghen E (2008) FALDH reverses the deleterious action of oxidative stress induced by lipid peroxidation product 4-hydroxynonenal on insulin signaling in 3T3-L1 adipocytes. Diabetes 57:1216-1226.
  7. Ahrén B, Sundkvist G (1995) Long-term effects of alloxan in mice. Int J Pancreatol 17:197-201.
  8. Calza P, Pazé C, Pelizzetti E, Zecchina A (2001) Shape-selective photocatalytic transformation of phenols in an aqueous medium. Chem Commun (Camb):2130-2131.
  9. Machado MC, Cunha JE, Penteado S, Bacchella T, Jukemura J, et al. (2000) Preoperative diagnosis of pancreatic leiomyosarcoma. Int J Pancreatol 28: 97-100
  10. Anuradha CV, Ravikumar P (2001) Restoration on tissue antioxidants by fenugreek seeds (Trigonella Foenum Graecum) in alloxan-diabetic rats. Indian J Physiol Pharmacol 45:408-420.
  11. Trejo-González A, Gabriel-Ortiz G, Puebla-Pérez AM, Huízar-Contreras MD, Munguía-Mazariegos MR, et al. (1996) A purified extract from prickly pear cactus (Opuntia fuliginosa) controls experimentally induced diabetes in rats. J Ethnopharmacol 55: 27-33.
  12. Alarcon- Aguilara FJ, Roman-Ramos R, Perez-Gutierrez S, Aguilar-Contreras A, Contreras-Weber CC, et al. (1998) Study of the anti-hyperglycemic effect of plants used as antidiabetics. J Ethnopharmacol 61: 101-110.
  13. Rajagopal K, Sasikala K (2008) Antihyperglycaemic and antihyperlipidaemic effects of Nymphaea stellata in alloxan-induced diabetic rats. Singapore Med J 49: 137-141.
  14. (1980) WHO Expert Committee on Diabetes Mellitus: second report. World Health Organ Tech Rep Ser 646: 1-80.
  15. Waltner-Law ME, Wang XL, Law BK, Hall RK, Nawano M, et al. (2002) Epigallocatechin gallate, a constituent of green tea, represses hepatic glucose production. J Biol Chem 277:34933-34940.
  16. Arora R, Chawla R, Puri SC, Sagar R, Singh S, et al. (2005) Radioprotective and antioxidant properties of low-altitude Podophyllum hexandrum (LAPH). J Environ Pathol Toxicol Oncol 24: 299-314.
  17. Ross R (1999) Atherosclerosis--an inflammatory disease. N Engl J Med 340:115-126.
  18. Springer JE, Gwag BJ, Sessler FM (1994) Central administration of the excitotoxin N-methyl-D-aspartate increases nerve growth factor mRNA in vivo. Neurotoxicology 15:483-489.
  19. DeFeudis FV, Drieu K (2000) Ginkgo biloba extract (EGb 761) and CNS functions: basic studies and clinical applications. Curr Drug Targets 1: 25-58.
  20. Zimmermann M, Colciaghi F, Cattabeni F, Di Luca M (2002) Ginkgo biloba extract: from molecular mechanisms to the treatment of Alzhelmer's disease. Cell Mol Biol (Noisy-le-grand) 48:613-623.
  21. Gohil K (2002) Genomic responses to herbal extracts: lessons from in vitro and in vivo studies with an extract of Ginkgo biloba. Biochem Pharmacol 64: 913-917.
  22. Akisü M, Kültürsay N, Coker I, Hüseyinov A (1998) Platelet-activating factor is an important mediator in hypoxic ischemic brain injury in the newborn rat. Flunarizine and Ginkgo biloba extract reduce PAF concentration in the brain. Biol Neonate 74:439-444.
  23. Chan AC, Rohan MJ, Hamid A, Azam A (2007) Emphysematous pyelonephritis in a diabetic patient with pelvic-ureteric stone. Med J Malaysia 62:166-167.
  24. Yagil R, Saran A, Etzion Z (1984) Camels' milk: for drinking only? Comp Biochem Physiol A Comp Physiol 78: 263-266.
  25. Korhonen H, Pihlanto A (2003) Food-derived bioactive peptides--opportunities for designing future foods. Curr Pharm Des 9:1297-1308.
  26. Al-Hashem F (2009) Camel’s milk protects against aluminum chloride-induced toxicity in the liver and kidney of white albino rats. Am J Biochem Biotechnol 5:98-109.
  27. Gorban AM, Izzeldin OM (2001) Fatty acids and lipids of camel milk and colostrum. Int J Food Sci Nutr 52: 283-287.
  28. Krishna G, Nath J, Ong T (1986) Inhibition of cyclophosphamide and mitomycin C-induced sister chromatid exchanges in mice by vitamin C. Cancer Res 46:2670-2674.
  29. Vijayalaxmi KK, Venu R (1999) In vivo anticlastogenic effects of L-ascorbic acid in mice. Mutat Res 438:47-51.
  30. Rao MV, Chinoy NJ, Suthar MB, Rajvanshi MI (2001) Role of ascorbic acid on mercuric chloride-induced genotoxicity in human blood cultures. Toxicol In Vitro 15: 649-654.
  31. Hurná E, Siklenka P, Hurná S (1997) Effect of selenium on cadmium genotoxicity investigated by micronucleus assay. Vet Med (Praha) 42:339-342.
  32. Cabrera C, Giménez R, López MC (2003) Determination of tea components with antioxidant activity. J Agric Food Chem 51: 4427-4435.
  33. Hassan NH, Fahmy MA, Farghaly AA, Hassan EE ( 2006) Anti-mutagenic effect of selenium and vitamins against the genotoxicity by cobalt chloride in mice. Cytologia 71: 213-222.
  34. Hurná E, Hurná S (2000) Protective effect of zinc on cadmium-induced micronuclei in V79 cells. J Trace Elem Med Biol 14: 55-57.
  35. van Boekel MA, Weerens CN, Holstra A, Scheidtweiler CE, Alink GM (1993) Antimutagenic effects of casein and its digestion products. Food Chem Toxicol 31: 731-737.
  36. Goeptar AR, Koeman JH, Van Boekel MA, Alink GM (1997) Impact of digestion on the antimutagenic activity of the milk protein casein. Nutr Res 17: 1363-1379.
  37. Konuspayeva G, Serikbayeva A, Loiseau G, Narmuratova M, Faye B (2004) In: Bernard, Faye, Palmated, Esenov (Eds.). Desertification Combat and Food Safety: The Added Value of Camel Producers. IOS Press, Amisterdam, Ashgabad, Turkmenistan: 158-167.
  38. Cai Y, Teranishi H, Aoshima K, Katoh T, Arai Y, et al. (2001) Development of the fluorometric ELISA method for determination of alpha1-microglobulinuria in a cadmium-polluted area in Japan. Int Arch Occup Environ Health 74: 514-518.
  39. Mal G, Sena DS, Jain VK, Sahani MS (2001) Therapeutic utility of camel milk as nutritional supplement in chronic pulmonary tuberculosis. Livestock Int:4-8.
  40. Agrawal RP, Budania S, Sharma P, Gupta R, Kochar DK, et al. (2007) Zero prevalence of diabetes in camel milk consuming Raica community of north-west Rajasthan, India. Diabetes Res Clin Pract 76:290-296.
  41. Trinder P (1969) Determination of blood glucose using an oxidase-peroxidase system with a non-carcinogenic chromogen. J Clin Pathol 22:158-161.
  42. Ohkawa H, Ohishi N, Yagi K (1979) Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem 95: 351-358.
  43. Koracevic D, Koracevic G, Djordjevic V, Andrejevic S, Cosic V (2001) Method for the measurement of antioxidant activity in human fluids. J Clin Pathol 54:356-361.
  44. Reitman S, Frankel S (1957) A colorimetric method for the determination of serum glutamic oxalacetic and glutamic pyruvic transaminases. Am J Clin Pathol 28:56-63.
  45. Szasz G, Rosenthal P, Fritzsche W (1969) Gamma-glutamyl-transpeptidase, leucine aminopeptidase and alkaline phosphatase. Comparison of 3724 serums. Schweiz Med Wochenschr 99:606-608.
  46. Allain CC, Poon LS, Chan CS, Richmond W, Fu PC (1974) Enzymatic determination of total serum cholesterol. Clin Chem 20: 470-475.
  47. Lopes-Virella MF, Stone P, Ellis S, Colwell JA (1977) Cholesterol determination in high-density lipoproteins separated by three different methods. Clin Chem 23:882-884.
  48. Vassault A, Grafmeyer D, de Graeve J, Cohen R, Beaudonnet A, et al. (1999) Quality specifications and allowable standards for validation of methods used in clinical biochemistry. Ann Biol Clin (Paris) 57: 685-695.
  49. Gornall AG, Bardawill CJ, David MM (1949) Determination of serum proteins by means of the biuret reaction. J Biol Chem 177:751-766.
  50. Fawcett JK, Scott JE (1960) A rapid and precise method for the determination of urea. J Clin Pathol 13: 156-159.
  51. schirmeister J, Willmann H, Kiefer H (1964) CRITICAL EVALUATION OF PLASMA CREATININE AS A TEST OF GLOMERULUS FILTRATE. Verh Dtsch Ges Inn Med 70:678-681.
  52. Bancroft J, Gutierrez P (1996) Erectile dysfunction in men with and without diabetes mellitus: a comparative study. Diabet Med 13: 84-89.
  53. Vetrichelvan T, Jegadeesan M, Devi BA (2002) Anti-diabetic activity of alcoholic extract of Celosia argentea Linn. seeds in rats. Biol Pharm Bull 25:526-528.
  54. Ho CT, Wang M, Wei GJ, Huang TC, Huang MT (2000) Chemistry and antioxidative factors in rosemary and sage. Biofactors 13:161-166.
  55. Park BH, Park JW (2001) The protective effect of Amomum xanthoides extract against alloxan-induced diabetes through the suppression of NFkappaB activation. Exp Mol Med 33: 64-68.
  56. Beg OU, Von Bahr-Lindrom H, Zaidi ZH, Jornvall H (1986) Characteristics of camel milk protein rich in proline identifies a new beta-casein fragment. Regul Pept 15:55-61
  57. (1996) Influence of intensive diabetes treatment on quality-of-life outcomes in the diabetes control and complications trial. Diabetes Care 19:195-203.
  58. Marles RG, Farnsworth NR (1994) Plants as sources of antidiabetic agents. Econ Med Plant Res 6:149-187.
  59. Abdel-Moneim A (1998) Effect of some medicinal plants and gliclazide on insulin release in vitro. J Egypt Ger Soc Zool 25: 423- 445.
  60. Broadhurst CL, Polansky MM, Anderson RA (2000) Insulin-like biological activity of culinary and medicinal plant aqueous extracts in vitro. J Agric Food Chem 48:849-852.
  61. Oliver-Bever B (1986) Medicinal plants in tropical west Africa Cambridge university press, London: 245-267.
  62. Ivorra MD, Payá M, Villar A (1989) A review of natural products and plants as potential antidiabetic drugs. J Ethnopharmacol 27: 243-275.
  63. Atta-Ur-Rahman, Zaman K (1989) Medicinal plants with hypoglycemic activity. J Ethnopharmacol 26: 1-55.
  64. KameswaraRao B, Giri R, Kesavulu MM, AppaRao (1997) Herbal medicine: in management of diabetes mellitus. ManpharVaidhyaPatrika 1: 33-35.
  65. Chakavarthy BK, Gupta S, Gambir SS, Gode KD (1980) Pancreatic beta cell regeneration. A novel antidiabetic mechanism of Pterocarpus marsupium Roxb. Indian Journal of Pharmacology 12: 123-127.
  66. Kamalakkannan N, Prince PS (2006) Antihyperglycaemic and antioxidant effect of rutin, a polyphenolic flavonoid, in streptozotocin-induced diabetic wistar rats. Basic Clin Pharmacol Toxicol 98: 97-103.
  67. Kameswara Rao B, Renuka Sudarshan P, Rajasekhar MD, Nagaraju N, Appa Rao Ch (2003) Antidiabetic activity of Terminalia pallida fruit in alloxan induced diabetic rats. J Ethnopharmacol 85: 169-172.
  68. Shibib BA, Khan LA, RahmanR (1993) Hypoglycaemic activity of Coccinia indica and Momordicacharantia in diabetic rats: depression of the hepatic gluconeogenic enzymes glucose-6-phosphatase and fructose-1,6-bisphosphatase and elevation of both liver and red-cell shunt enzyme glucose-6-phosphate dehydrogenase. Biochem J 292: 267-270.
  69. Rawi SM, Abdelmonelm A, Ahmed OM (1998) Studies on the effect of garlic oil and glibenclamide on alloxan diabetic rats. Egypt J Zool 30: 211-228.
  70. Mathé D (1995) Dyslipidemia and diabetes: animal models. Diabete Metab 21: 106-111.
  71. Ulicná O, Volkovová K, Istvánová B (1996) Bioenergetics of liver mitochondria in rats in experimental insulin-dependent diabetes. Bratisl Lek Listy 97: 619-624.
  72. Wasan KM, Ng SP, Wong W, Rodrigues BB (1998) Streptozotocin- and alloxan-induced diabetes modifies total plasma and lipoprotein lipid concentration and composition without altering cholesteryl ester transfer activity. Pharmacol Toxicol 83: 169-175.
  73. Tsutsumi K, Inoue Y, Shima A, Murase T (1995) Correction of hypertriglyceridemia with low high-density lipoprotein cholesterol by the novel compound NO-1886, a lipoprotein lipase-promoting agent, in STZ-induced diabetic rats. Diabetes 44: 414-417.
  74. Murray RK, Granner DK, Mayes PA, Rodwell VW (2000) Harper’sbiochemistry (25th edn) Stanford, CT: Appleton and Lange: 610-617.
  75. Marles RG, Farnsworth NR (1994) Plants as sources of antidiabetic agents. Econ Med Plant Res 6: 149-187.
  76. Sepici-Dincel A, Açikgöz S, Cevik C, Sengelen M, Yesilada E (2007) Effects of in vivo antioxidant enzyme activities of myrtle oil in normoglycaemic and alloxan diabetic rabbits. J Ethnopharmacol 110: 498-503.
  77. Horie S, Ishii H, Suga T (1981) Changes in peroxisomal fatty acid oxidation in the diabetic rat liver. J Biochem 90: 1691-1696.
  78. Memisogullari R, Bakan E (2004) Levels of ceruloplasmin, transferrin, and lipid peroxidation in the serum of patients with Type 2 diabetes mellitus. J Diabetes Complications 18: 193-197.
  79. Suresh Y, Das UN (2003) Long-chain polyunsaturated fatty acids and chemically induced diabetes mellitus. Effect of omega-3 fatty acids. Nutrition 19: 213-228.
  80. Hernandez T, Coulson RA (1967) Amino acid excretion in the alligator. Comp Biochem Physiol 23: 775-784.
  81. Maxine M, Benjamin BS (1985) Outline of veterinary clinical pathology (3rdedn) Colorado state university, printed in India at Rakha printers PVT. LTD., New Delhi.
  82. Mohan KI, Das UN (2001) Prevention of chemically induced diabetes mellitus in experimental animals by polyunsaturated fatty acids. Nutrition 17: 126-151.
  83. Mohan IK, Das UN (1998) Effect of L-arginine-nitric oxide system on chemical-induced diabetes mellitus. Free Radic Biol Med 25: 757-765.
Citation: Hassan NS, Emam MA (2012) Protective Effect of Camel Milk and Ginkgo biloba Extract Against Alloxan-Induced Diabetes in Rats. J Diabetes Metab 3:231.

Copyright: © 2012 Hassan NS, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.